澳华内镜(688212) - 2024 Q4 - 年度业绩

Financial Performance - Total revenue for 2024 reached RMB 748.56 million, a year-on-year increase of 10.39%[3] - Net profit attributable to shareholders of the parent company was RMB 21.32 million, a decrease of 63.15% compared to the previous year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB -6.99 million, indicating a significant decline[3] - Basic earnings per share decreased by 62.79% to RMB 0.16[3] Assets and Equity - The company's total assets increased by 9.61% to RMB 1,748.35 million at the end of the reporting period[4] - The company's equity attributable to shareholders decreased by 1.00% to RMB 1,366.20 million[4] Market and Operational Challenges - The company faced limited domestic revenue growth due to a decrease in procurement activities in the domestic terminal market[5] - The company anticipates challenges in meeting performance targets set in previous stock incentive plans, impacting financial results[5] Investment and Growth Strategies - The company expanded its overseas marketing network, leading to revenue growth in international markets[5] - Increased investment in new technology and product development resulted in higher sales, management, and R&D expenses, outpacing revenue growth[5]